CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Dimerix Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Dimerix Ltd
425 Smith Street, Fitzroy
Phone: +61 300813321p:+61 300813321 MELBOURNE, VIC  3065  Australia Ticker: DXBDXB
Business Summary
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20256/30/2025Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board MarkDiamond 12/1/2023 12/1/2023
Chief Executive Officer, Managing Director, Director NinaWebster 1/1/2021 8/27/2018
Chief Financial Officer, Company Secretary MichaelTonroe 1/29/2026 1/29/2026
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Dimerix Bioscience Pty Ltd L 11 63 Exhibition Street Melbourne VIC Australia

Business Names
Business Name
Dimerix Bioscience Ltd
DXB
DXBDC
Harrington Group Limited
Sun Biomedical Laboratories Inc.
Sun Biomedical Limited

General Information
Outstanding Shares: 600,396,776 (As of 12/31/2025)
Shareholders: 7,064
Stock Exchange: ASX
Fax Number: +61 893888256


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, July 19, 2026